Ashira D. Blazer, MD, MSCI; Karen H. Costenbader, MD, MPH
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from AstraZeneca.
The design of this program addresses the needs of rheumatology clinicians and other specialists involved in the care of patients with systemic lupus erythematosus (SLE).
Despite the plethora of investigational agents to treat SLE that have been studied extensively in clinical trials over the last several decades, very few therapies have ever become available to treat this complex, heterogeneous disease. However, 2021 ushered in US Food and Drug Administration (FDA) approvals for a novel targeted therapy to treat SLE and 2 options for treating lupus nephritis. At the same time, researchers and clinicians have been fervently working to improve disease assessment strategies and set realistic treatment goals for patients with SLE. As new approaches to disease assessment and targeted therapies in SLE become available, optimization of the day-to-day management of SLE must continue to evolve. In this Point-of-Care 101™ Microlearning Series, 2 expert rheumatologists will provide focused education on comprehensive patient evaluation, clinical profiles of currently available biologic therapies, and best practices for individualizing disease management in patients with SLE. Utilizing a multimedia delivery format that combines text and video, this educational series meets the needs of busy clinician learners who wish to stay current on the evolving best practices in managing patients with SLE.
Upon completion of this activity, the participant should be better able to:
- Discuss the mechanistic rationale and evidence for efficacy and safety of new targeted therapies in moderate-to-severe SLE
Ashira D. Blazer, MD, MSCI
Assistant Professor of Medicine
Weil Cornell Medical College
Assistant Attending Physician
Hospital for Special Surgery
New York, New York
Karen H. Costenbader, MD, MPH
Professor of Medicine, Harvard Medical School
Michael E. Weinblatt, MD, Distinguished Chair in Rheumatology
Division of Rheumatology, Immunology, and Allergy
Lupus Program Director
Brigham and Women's Hospital
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour(s) (which includes 0.1 hour(s) of pharmacology).
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or email@example.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 100% on the posttest, and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Ashira D. Blazer, MD, MSCI: Honoraria: Novartis Pharmaceuticals Corporation; Speakers Bureau: GlaxoSmithKline plc
Karen H. Costenbader, MD, MPH: Consulting Fee: Amgen Inc., AstraZeneca plc, GlaxoSmithKline plc; Contracted Research: Exagen Inc., Gilead Sciences, Inc., Merck & Co., Inc., Eli Lilly and Company, Janssen Pharmaceutical Companies; Stock Shareholder: Celgene Corporation; Stock Option Holder: Neutrolis, Inc.
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kristin Delisi, NP, Celeste Collazo, MD, Rose O'Connor, PhD, Jim Kappler, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13, and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.25
credit type CME/CE
From Patient Evaluations to New Targeted Therapies